IGF-1, IGFBP3, ALS Normative Ranges in Healthy Pediatric Spanish Population (EDISON)
This study is currently recruiting participants.
Verified April 2013 by Ipsen
Sponsor:
Ipsen
Information provided by (Responsible Party):
Ipsen
ClinicalTrials.gov Identifier:
NCT01676090
First received: August 22, 2012
Last updated: April 22, 2013
Last verified: April 2013
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
Purpose
To determine the normative ranges of the Insulin-like Growth Factor 1 (IGF-1), Insulin-like growth factor-binding protein 3 (IGFBP-3), Acid-Labile Subunit (ALS) according to age, sex and pubertal stage of a healthy paediatric Spanish population.
| Condition |
|---|
|
IGF-1 Deficiency |
| Study Type: | Observational |
| Study Design: | Time Perspective: Cross-Sectional |
| Official Title: | An Epidemiologic, Descriptive and Cross-sectional Study of the IGF-1, IGFBP-3 and ALS Normative Ranges in a Healthy Paediatric Spanish Population, Divided Into Chronological Age, Sex and Pubertal Stage |
Resource links provided by NLM:
Further study details as provided by Ipsen:
Primary Outcome Measures:
- IGF-1 levels according to age, sex and pubertal stage in healthy paediatric volunteers [ Time Frame: At the time of participant's single study visit (day 1) ] [ Designated as safety issue: No ]
Secondary Outcome Measures:
- IGFBP-3 levels according to age, sex and pubertal stage in healthy paediatric volunteers [ Time Frame: At the time of participant's single study visit (day 1) ] [ Designated as safety issue: No ]
- ALS levels according to age, sex and pubertal stage in healthy paediatric volunteers [ Time Frame: At the time of participant's single study visit (day 1) ] [ Designated as safety issue: No ]
| Estimated Enrollment: | 1150 |
| Study Start Date: | July 2012 |
| Estimated Study Completion Date: | October 2013 |
| Estimated Primary Completion Date: | October 2013 (Final data collection date for primary outcome measure) |
Eligibility| Ages Eligible for Study: | up to 18 Years |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | Yes |
| Sampling Method: | Non-Probability Sample |
Study Population
Healthy paediatric Spanish population
Criteria
Inclusion Criteria:
- Children of either sex of Caucasian parents
- Age: newborns up to and including 18 years of age
- Length/height, weight and body mass index (BMI) within the mean +/- 2SD (Standard Deviation) and in accordance with the growth charts of the 2010 Spanish cross-sectional growth study (Carrascosa Lezcano et al 2010)
- Signed consent by at least one parent or legal guardian (if subject is ≤18 years) and by subject if ≥12 years
Exclusion Criteria:
- Early or advanced puberty (pubertal signs: between 8 and 9 years old in girls, and between 9 and 10 years old in boys), or delayed puberty (no puberty onset in ≥ 13 year-old girls, and in ≥ 14 year-old boys)
- Chronic diseases including, but not limited to, endocrinologic diseases, chromosomal diseases, chronic diseases of renal, hepatic and/or cardiac aetiology, and tumour processes
- An acute disease during the last two weeks prior to recruitment
- Any clinically significant out-of-range lab value
- Healthy paediatric volunteers who are under medical treatment (contraception permitted)
- A family history of short stature (either parent < P3)
- Children born small for gestational age (birth weight, length, or head circumference < P10)
- Adopted children or conceived through in vitro fertilization ( IVF )
- Subjects who are unwilling or unable in the opinion of the investigator or sponsor to undergo all the study procedures
Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT01676090
Contacts
| Contact: Ipsen Recruitment Enquiries | clinical.trials@ipsen.com |
Locations
| Spain | |
| Fundación Sant Joan de Deu | Recruiting |
| Barcelona, Spain | |
| Hospital Universitari Vall d´Hebron | Recruiting |
| Barcelona, Spain | |
| Hospital de Cruces | Recruiting |
| Bilbao, Spain | |
| Hospital Infantil Universitario Niño Jesús | Not yet recruiting |
| Madrid, Spain | |
| Hospital 12 de Octubre | Not yet recruiting |
| Madrid, Spain | |
| Hospital Universitario La Paz | Recruiting |
| Madrid, Spain | |
| Hospital Clínico Universitario de Santiago de Compostela | Recruiting |
| Santiago de Compostela, Spain | |
| Hospital Universitario Nuestra Señora de Valme | Recruiting |
| Sevilla, Spain | |
| Hospital Miguel Servet | Recruiting |
| Zaragoza, Spain | |
Sponsors and Collaborators
Ipsen
Investigators
| Study Director: | Arturo Rojas De Filippis, MD | Ipsen |
More Information
No publications provided
| Responsible Party: | Ipsen |
| ClinicalTrials.gov Identifier: | NCT01676090 History of Changes |
| Other Study ID Numbers: | A-92-52800-020 |
| Study First Received: | August 22, 2012 |
| Last Updated: | April 22, 2013 |
| Health Authority: | Spain: Agencia Española de Medicamentos y Productos Sanitarios |
ClinicalTrials.gov processed this record on May 21, 2013